Boothbay Fund Management, LLC Savara Inc Transaction History

Boothbay Fund Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.6 - $2.82 $84,232 - $148,458	52,645 New	52,645 $102,000
Q2 2022 Aug 15, 2022	SELL	$1.1 - $1.58 $169,689 - $243,735	-154,263 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $74,690 - $103,807	-63,297 Reduced 29.09%	154,263 $213,000
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $24,539 - $37,214	16,251 Added 8.07%	217,560 $370,000
Q1 2021 May 17, 2021	BUY	$1.17 - $2.33 $235,531 - $469,049	201,309 New	201,309 $419,000
Q3 2020 Nov 16, 2020	SELL	$1.09 - $2.21 $125,350 - $254,150	-115,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $207,000 - $350,750	115,000 New	115,000 $286,000
Q4 2019 Feb 14, 2020	SELL	$0.71 - $4.91 $19,831 - $137,141	-27,931 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.16 - $3.2 $60,330 - $89,379	27,931 New	27,931 $74,000
Q2 2018 Aug 14, 2018	SELL	$8.55 - $13.76 $102,600 - $165,120	-12,000 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$8.99 - $14.95 $107,880 - $179,400	12,000 New	12,000 $110,000

128

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $365M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.